Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 9/2016

01-09-2016 | Clinical Investigation

Safety and Efficacy of Percutaneous Biliary Covered Stent Placement in Patients with Malignant Biliary Hilar Obstruction; Correlation with Liver Function

Authors: Hyeran Hyun, Sun Young Choi, Kyung Ah Kim, Soo Bin Ko

Published in: CardioVascular and Interventional Radiology | Issue 9/2016

Login to get access

Abstract

Purpose

To estimate the safety and efficacy of percutaneous ePTFE-covered biliary stent placement and the relationship between underlying liver function and stent patency in patients with malignant hilar obstruction.

Materials and Methods

From March 2012 to June 2015, 41 patients [22 females, 19 males; mean age 69.8 (range 34–94) years] with malignant biliary obstruction underwent percutaneous biliary stent placement (31 patients with unilateral, 10 patients with bilateral side-by-side). Cumulative patient survival and stent patency rate curves were derived using the Kaplan–Meier method. A Cox model was used to explore the relationship between liver function and patient survival, and also biliary stent patency. Pearson correlation coefficient was used to analyze the relationship between patient survival and stent patency.

Results

Technical success rate was 100 % and clinical success rate was 95 %. During follow-up, four complications occurred (two bilomas and two cases of acute cholecystitis) and were treated successfully with percutaneous drainage. No other complication occurred. Mean serum bilirubin level was 11.34 ± 7.35 mg/dL before drainage and 5.00 ± 4.83 mg/dL 2 weeks after stent placement. The median patent survival duration was 147 days (95 % CI, 69.6–224.4 days). The median stent patency duration was 101 days (95 % CI, 70.0–132.0 days). The cumulative stent patency rates at 1, 3, 6, and 12 months were 97, 57.6, 30.3, and 17.0 %, respectively. Child–Pugh score was correlated significantly with patient survival (P = 0.011) and stent patency (P = 0.007). MELD score was correlated significantly with stent patency (P = 0.044). There was a correlation between patient survival and stent patency (r = 0.778, P < 0.001).

Conclusion

Percutaneous placement of ePTFE-covered biliary stent was a safe and an effective method for malignant biliary obstruction. Underlying liver function seemed to be one of the important factors affecting patient survival and stent patency, and stent patency showed statistically significant correlation with patient survival.
Literature
1.
Kumaran V, Gulati S, Paul B, Pande K, Sahni P, Chattopadhyay K. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. Eur Radiol. 2002;12(8):1993–9.CrossRefPubMed
2.
Adam A, Chetty N, Roddie M, Yeung E, Benjamin IS. Self-expandable stainless steel endoprostheses for treatment of malignant bile duct obstruction. AJR Am J Roentgenol. 1991;156(2):321–5.CrossRefPubMed
3.
Mathieson JR, McLoughlin RF, Cooperberg PL, et al. Malignant obstruction of the common bile duct: long-term results of Gianturco-Rosch metal stents used as initial treatment. Radiology. 1994;192(3):663–7.CrossRefPubMed
4.
Lammer J, Hausegger KA, Fluckiger F, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology. 1996;201(1):167–72.CrossRefPubMed
5.
Hausegger KA, Thurnher S, Bodendorfer G, et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. AJR Am J Roentgenol. 1998;170(2):403–8.CrossRefPubMed
6.
Molnar W, Stockum AE. Relief of obstructive jaundice through percutaneous transhepatic catheter—a new therapeutic method. Am J Roentgenol. 1974;122(2):356–67.CrossRef
7.
Pereiras RV Jr, Rheingold OJ, Huston D, et al. Relief of malignant obstructive jaundice by percutaneous insertion of a permanent prosthesis in the biliary tree. Ann Intern Med. 1978;89(5 Pt 1):583–9.
8.
Lammer J. Biliary endoprostheses. Plastic versus metal stents. Radiol Clin North Am. 1990;28(6):1211–22.PubMed
9.
Morgan RA, Adam AN. Malignant biliary disease: percutaneous interventions. Tech Vasc Interv Radiol. 2001;4(3):147–52.CrossRefPubMed
10.
Rossi P, Bezzi M, Salvatori FM, Panzetti C, Rossi M, Pavia G. Clinical experience with covered Wallstents for biliary malignancies: 23-month follow-up. Cardiovasc Intervent Radiol. 1997;20(6):441–7.CrossRefPubMed
11.
Born P, Neuhaus H, Rosch T, et al. Initial experience with a new, partially covered Wallstent for malignant biliary obstruction. Endoscopy. 1996;28(8):699–702.CrossRefPubMed
12.
Schoder M, Rossi P, Uflacker R, et al. Malignant biliary obstruction: treatment with ePTFE-FEP–covered endoprostheses—initial technical and clinical experiences in a multicenter trial 1. Radiology. 2002;225(1):35–42.CrossRefPubMed
13.
Lee MJ, Dawson SL, Mueller PR, et al. Percutaneous management of hilar biliary malignancies with metallic endoprostheses: results, technical problems, and causes of failure. Radiographics. 1993;13(6):1249–63.CrossRefPubMed
14.
Hausegger KA, Kleinert R, Lammer J, Klein GE, Fluckiger F. Malignant biliary obstruction: histologic findings after treatment with self-expandable stents. Radiology. 1992;185(2):461–4.CrossRefPubMed
15.
Gosain S, Bonatti H, Smith L, et al. Gallbladder stent placement for prevention of cholecystitis in patients receiving covered metal stent for malignant obstructive jaundice: a feasibility study. Dig Dis Sci. 2010;55(8):2406–11.CrossRefPubMed
16.
Dumonceau JM, Tringali A, Blero D, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012;44(3):277–98.CrossRefPubMed
17.
Brountzos EN, Ptochis N, Panagiotou I, Malagari K, Tzavara C, Kelekis D. A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting. Cardiovasc Intervent Radiol. 2007;30(1):66–73.CrossRefPubMed
18.
Gandini R, Fabiano S, Pipitone V, et al. Management of biliary neoplastic obstruction with two different metallic stents implanted in one session. Cardiovasc Intervent Radiol. 2005;28(1):48–52.CrossRefPubMed
19.
Tesdal IK, Adamus R, Poeckler C, Koepke J, Jaschke W, Georgi M. Therapy for biliary stenoses and occlusions with use of three different metallic stents: single-center experience. J Vasc Interv Radiol. 1997;8(5):869–79.CrossRefPubMed
20.
Carr-Locke DL. Metal stents for distal biliary malignancy: have we got you covered? Gastrointest Endosc. 2005;61(4):534–6.CrossRefPubMed
21.
Gwon DI, Ko GY, Kim JH, et al. A comparative analysis of PTFE-covered and uncovered stents for palliative treatment of malignant extrahepatic biliary obstruction. AJR Am J Roentgenol. 2010;195(6):W463–9.CrossRefPubMed
22.
Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol. 2010;33(1):97–106.CrossRefPubMed
23.
Krokidis M, Fanelli F, Orgera G, et al. Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE/FEP–covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol. 2011;34(2):352–61.CrossRefPubMed
24.
Naitoh I, Hayashi K, Nakazawa T, et al. Side-by-side versus stent-in-stent deployment in bilateral endoscopic metal stenting for malignant hilar biliary obstruction. Dig Dis Sci. 2012;57(12):3279–85.CrossRefPubMed
25.
Fanelli F, Orgera G, Bezzi M, Rossi P, Allegritti M, Passariello R. Management of malignant biliary obstruction: technical and clinical results using an expanded polytetrafluoroethylene fluorinated ethylene propylene (ePTFE/FEP)-covered metallic stent after 6-year experience. Eur Radiol. 2008;18(5):911–9.CrossRefPubMed
26.
Son RC, Gwon DI, Ko HK, Kim JW, Ko GY. Percutaneous unilateral biliary metallic stent placement in patients with malignant obstruction of the biliary hila and contralateral portal vein steno-occlusion. Korean J Radiol. 2015;16(3):586–92.CrossRefPubMedPubMedCentral
27.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.CrossRefPubMed
28.
Cholongitas E, Papatheodoridis G, Vangeli M, Terreni N, Patch D, Burroughs A. Systematic review: the model for end-stage liver disease–should it replace Child–Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–89.CrossRefPubMed
29.
Farnsworth N, Fagan SP, Berger DH, Awad SS. Child–Turcotte–Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg. 2004;188(5):580–3.CrossRefPubMed
30.
Wedd J, Bambha KM, Stotts M, et al. Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for end-stage liver disease scores and cirrhosis awaiting liver transplantation. Liver Transpl. 2014;20(10):1193–201.CrossRefPubMedPubMedCentral
31.
Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child–Turcotte–Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol. 2005;42(5):700–6.CrossRefPubMed
32.
Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52(1):134–9.CrossRefPubMedPubMedCentral
33.
Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology. 2001;34(4 Pt 1):671–6.CrossRefPubMed
34.
Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int. 1998;54(2):518–24.CrossRefPubMed
Metadata
Title
Safety and Efficacy of Percutaneous Biliary Covered Stent Placement in Patients with Malignant Biliary Hilar Obstruction; Correlation with Liver Function
Authors
Hyeran Hyun
Sun Young Choi
Kyung Ah Kim
Soo Bin Ko
Publication date
01-09-2016
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 9/2016
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-016-1375-5

Other articles of this Issue 9/2016

CardioVascular and Interventional Radiology 9/2016 Go to the issue

Technical Note

18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience

Clinical Investigation

Pharmacomechanical Thrombectomy in Paget–Schroetter Syndrome

Letter to the Editor

Accessory Left Gastric Artery from Left Hepatic Artery is a Potential Risk for Radioembolization Complications

Letter to the Editor

Endovascular Repair of a Type 1a Endoleak After Ch-EVAR with a b-EVAR

Case Report

Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia

Letter to the Editor

Regarding “Radioembolization: Is Prophylactic Embolization of Hepaticoenteric Arteries Necessary? A Systematic Review”